Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with a terminal chronic liver disease have a disordered bone metabolism resulting in a higher risk of falling ill with osteoporosis. Although liver transplantation restores liver function, immunosuppressive therapy (especially corticosteroids) after transplantation increases again the risk of osteoporosis and bone fragility. Zoledronate, a bisphosphonate, slows down the destruction of bone. The purpose of this study is to determine whether bisphosphonates are effective in the prevention of osteoporosis following immunosuppressive therapy after liver transplantation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• primary liver transplantation

• retransplantation within two weeks

• written informed consent

• Age ≥ 18 years

Exclusion Criteria:

• chronic kidney disease:

• Creatinine Clearance < 35 ml/min or Serum Creatinine > 2,5 mg/dl

• known hypersensitivity to Zoledronate, or any of the recipients of the drug

• bone specific medication (Bisphosphonate, Fluoride, Calcitonin) within the last three months before liver transplantation